Market Overview

The Global Glucagon-like Peptide-1 (GLP-1) Agonists Market was valued at USD 12,903.9 million in 2023 and is expected to reach USD 16,473.7 million by 2031 while growing at a CAGR of 3.1% during the forecast period (2024-2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global glucagon-like peptide-1 (GLP-1) agonists market growth. Glucagon-like peptide-1 (GLP-1) agonists, utilized in type 2 diabetes mellitus (T2DM) treatment, mimic the effects of natural GLP-1. This intestinal hormone stimulates insulin secretion from pancreatic beta cells, suppresses glucagon secretion, decelerates gastric emptying, and enhances satiety.

The increasing prevalence of Type 2 Diabetes, coupled with ongoing research and development efforts resulting in the discovery of new GLP-1 agonists with enhanced efficacy, safety, and patient convenience profiles, propels the glucagon-like peptide-1 (GLP-1) agonists market. Nonetheless, obstacles such as the high cost of treatment and concerns regarding safety and tolerability impede the market's growth.

Furthermore, the global glucagon-like peptide-1 (GLP-1) agonists industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Drugs Analysis

The Global Glucagon-like Peptide-1 (GLP-1) Agonists Market is segmented among Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide, based on Drugs. In 2023, Dulaglutide accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Glucagon-like Peptide-1 (GLP-1) Agonists Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Pfizer, and Twist Bioscience Corporation.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Glucagon-like Peptide-1 (GLP-1) Agonists Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Segmentation, By Drugs

• Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Share Analysis, By Drugs

• Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Growth Analysis, By Drugs

• Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends, By Drugs

o Dulaglutide

o Exenatide

o Liraglutide

o Lixisenatide

o Semaglutide

6. Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Segmentation, By Region

• Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Share Analysis, By Region

• Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Growth Analysis, By Region

• Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

7. Competitive Landscape

• Novo Nordisk*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• Sanofi

• Eli Lilly

• AstraZeneca

• Boehringer Ingelheim

• Pfizer

• Twist Bioscience Corporation

*Similar analysis will be provided for each company listed above.